Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate.

Abstract

Ten women with endometriosis were treated with medroxyprogesterone acetate (MPA), 150 mg intramuscularly every second week. After 2 weeks, there was a significant (8%) decrease in the high-density lipoprotein (HDL) concentration. This reduction became more pronounced after 8 and 24 weeks' medication. The HDL reduction was confined to the HDL2 subfraction, which was decreased by 15%, 33%, and 58% after 2, 8, and 24 weeks, respectively; there was no significant change in the HDL3 concentration. During treatment, there was a continuous increase in the mean MPA plasma level and a strong inverse correlation between this level and the mean HDL and HDL2 cholesterol concentrations. It was concluded that MPA affects HDL metabolism in a dose-dependent way and in the same direction as other progestins.

Statistics

0100020003000'04'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

2,090 Citations

Semantic Scholar estimates that this publication has 2,090 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Fhraeus1986LipoproteinCD, title={Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate.}, author={Lars F{\aa}hraeus and Adam Sydsj{\"{o} and Lars Wallentin}, journal={Fertility and sterility}, year={1986}, volume={45 4}, pages={503-6} }